drugset / Press release
AACR 2023, RSO-021, a first-in-class treatment
2023-04-15 · RS Oncology LLC · original rsoncology.com ↗
Our Chief Science Officer, Dr. Brian Cunniff successfully presented key research at AACR 2023. Characterization of immune cell phenotypes in patient derived malignant pleural effusion treated with thiostrepton. Thiostrepton (TS) is a covalent inhibitor of mitochondrial Peroxiredoxin 3 (PRX3). Home About Science Pipeline Patients News & Events Publications Contact Home About Science Pipeline Patients News & Events Publications Contact bottom of page
The release as fetched from its publisher. rsoncology.com ↗